126 related articles for article (PubMed ID: 25525858)
21. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
22. Novel targeted agents for the treatment of advanced breast cancer.
de la Vega M; Díaz-Cantón E; Alvarez RH
Future Med Chem; 2012 May; 4(7):893-914. PubMed ID: 22571614
[TBL] [Abstract][Full Text] [Related]
23. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Blachly JS; Baiocchi RA
Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
[TBL] [Abstract][Full Text] [Related]
24. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
25. New drugs for the treatment of lymphoma.
Paoluzzi L; Kitagawa Y; Kalac M; Zain J; O'Connor OA
Hematol Oncol Clin North Am; 2008 Oct; 22(5):1007-35, x. PubMed ID: 18954749
[TBL] [Abstract][Full Text] [Related]
26. Mantle cell lymphoma in relapse: the role of emerging new drugs.
Diefenbach CS; O'Connor OA
Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
[TBL] [Abstract][Full Text] [Related]
27. Pharmacotherapy of neuroblastoma.
George RE; Diller L; Bernstein ML
Expert Opin Pharmacother; 2010 Jun; 11(9):1467-78. PubMed ID: 20408767
[TBL] [Abstract][Full Text] [Related]
28. Lymphoma: looking from the present to the future.
Cheson BD; Zhu J
Chin Clin Oncol; 2015 Mar; 4(1):2. PubMed ID: 25841709
[No Abstract] [Full Text] [Related]
29. [Genetic mutations in malignant lymphoma: the molecular and clinical significances and the application for development of molecular targeting therapeutics].
Tomita A
Rinsho Ketsueki; 2013 Oct; 54(10):1788-98. PubMed ID: 24064830
[No Abstract] [Full Text] [Related]
30. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
31. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
Frau M; Biasi F; Feo F; Pascale RM
Mol Aspects Med; 2010 Apr; 31(2):179-93. PubMed ID: 20176048
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.
Zheng W; Guan M; Zhu L; Cai Z; Chung V; Huang H; Yen Y
Anticancer Res; 2010 Jun; 30(6):1921-30. PubMed ID: 20651335
[TBL] [Abstract][Full Text] [Related]
33. Rethinking clinical response and outcome assessment in a biologic age.
Cheson BD
Curr Oncol Rep; 2015 Jun; 17(6):27. PubMed ID: 25975729
[TBL] [Abstract][Full Text] [Related]
34. Targeting the NF-κB pathway in cancer therapy.
Erstad DJ; Cusack JC
Surg Oncol Clin N Am; 2013 Oct; 22(4):705-46. PubMed ID: 24012396
[TBL] [Abstract][Full Text] [Related]
35. NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.
Breccia M; Alimena G
Expert Opin Ther Targets; 2010 Nov; 14(11):1157-76. PubMed ID: 20858024
[TBL] [Abstract][Full Text] [Related]
36. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
37. Emerging new anticancer biological therapies in 2013 (haematological malignancies).
Plawny L; Ries F
Curr Opin Oncol; 2014 May; 26(3):363-70. PubMed ID: 24663027
[TBL] [Abstract][Full Text] [Related]
38. Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.
Waibel M; Gregory G; Shortt J; Johnstone RW
Curr Opin Hematol; 2014 Jul; 21(4):297-308. PubMed ID: 24811162
[TBL] [Abstract][Full Text] [Related]
39. Using NF-κB as a molecular target for theranostics in radiation oncology research.
Liu YC; Chiang IT; Hsu FT; Hwang JJ
Expert Rev Mol Diagn; 2012 Mar; 12(2):139-46. PubMed ID: 22369374
[TBL] [Abstract][Full Text] [Related]
40. [Malignant lymphoma].
Kato H; Kinoshita T
Rinsho Ketsueki; 2016 Mar; 57(3):249-59. PubMed ID: 27076235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]